Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024
February 05, 2024 07:00 ET | FibroGen, Inc.
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host Part I of a virtual KOL investor event series on Tuesday, February 13, 2024 at 10:30 AM...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports First Quarter 2023 Financial Results
May 08, 2023 16:01 ET | FibroGen, Inc.
• Topline Data From Four Phase 3 Trials Expected Through 3Q 2023 • Completed Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value • Entered Into...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report First Quarter 2023 Financial Results
April 24, 2023 07:00 ET | FibroGen, Inc.
SAN FRANCISCO, April 24, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2023 financial results on Monday, May 8 after the market close. FibroGen will also...
LAPIS Semiconductor’s Speech Synthesis ICs Equipped with Playback Anomaly Detection Function
July 23, 2020 11:00 ET | ROHM Semiconductor
Yokohama, Japan and Santa Clara, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- ROHM Group company LAPIS Semiconductor recently announced the automotive speech synthesis ICs, ML2253x series, optimized...
LAPIS Semiconductor's New Multiband Wireless Communication LSI Optimized for Smart Meters World-wide
November 12, 2019 11:00 ET | ROHM Semiconductor
Yokohama, Japan and Santa Clara, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- ROHM Group company LAPIS Semiconductor recently announced the availability of a multiband (sub-1GHz/2.4GHz) wireless...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Announces First Patient Dosed in LAPIS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients With Locally Advanced Pancreatic Cancer  
October 23, 2019 07:00 ET | FibroGen, Inc
SAN FRANCISCO, Oct. 23, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced the dosing of the first patient in the LAPIS Phase 3 clinical study of pamrevlumab in patients with...
LAPIS Semiconductor's 16-bit General-Purpose MCUs Equipped with Safety Functions
March 12, 2019 15:19 ET | ROHM Semiconductor
Yokohama and Santa Clara, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- ROHM Group company LAPIS Semiconductor recently announced the availability of the ML62Q1300/1500/1700 Group of general-purpose...
The Industry’s First Dual-Mode LPWA (Low Power Wide Area) Compliant Wireless Communication LSI
September 05, 2017 11:35 ET | ROHM Semiconductor
Yokohama, Japan and Santa Clara, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Yokohama and Santa Clara, Calif., – September 5, 2017 – ROHM Group company LAPIS Semiconductor has recently announced the...
LAPIS Semiconductor’s Breakthrough Soil Environment Sensor
June 27, 2017 18:10 ET | ROHM Semiconductor
Yokohama, Japan and Santa Clara, Calif., June 27, 2017 (GLOBE NEWSWIRE) -- ROHM Group company LAPIS Semiconductor has recently announced the development of a soil environment sensor ideal for...